LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Celldex Therapeutics Inc

Fechado

SetorSaúde

30.29 -4.84

Visão Geral

Variação de preço das ações

24h

Atual

Mín

30.09

Máximo

31.22

Indicadores-chave

By Trading Economics

Rendimento

-14M

-81M

Vendas

75K

75K

EPS

-1.22

Margem de lucro

-108,422.667

Funcionários

198

EBITDA

-7.8M

-81M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+69.8% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

501M

2.1B

Abertura anterior

35.13

Fecho anterior

30.29

Sentimento de Notícias

By Acuity

100%

0%

324 / 349 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

Celldex Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mar. de 2026, 17:33 UTC

Notícias Principais

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 de mar. de 2026, 17:00 UTC

Notícias Principais

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 de mar. de 2026, 16:03 UTC

Notícias Principais

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 de mar. de 2026, 14:50 UTC

Grandes Movimentos do Mercado

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 de mar. de 2026, 14:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 de mar. de 2026, 14:29 UTC

Notícias Principais

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 de mar. de 2026, 14:16 UTC

Notícias Principais

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 de mar. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 19:16 UTC

Conversa de Mercado
Notícias Principais

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 de mar. de 2026, 19:07 UTC

Conversa de Mercado

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 de mar. de 2026, 19:04 UTC

Conversa de Mercado

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 de mar. de 2026, 19:03 UTC

Conversa de Mercado
Notícias Principais

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 19:02 UTC

Conversa de Mercado
Notícias Principais

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 de mar. de 2026, 18:12 UTC

Conversa de Mercado

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 de mar. de 2026, 17:36 UTC

Notícias Principais

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 de mar. de 2026, 17:34 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 de mar. de 2026, 17:29 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 de mar. de 2026, 16:38 UTC

Conversa de Mercado

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 de mar. de 2026, 16:32 UTC

Conversa de Mercado
Notícias Principais

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 de mar. de 2026, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de mar. de 2026, 15:43 UTC

Conversa de Mercado
Notícias Principais

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 15:25 UTC

Conversa de Mercado

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 de mar. de 2026, 15:00 UTC

Notícias Principais

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 de mar. de 2026, 14:36 UTC

Conversa de Mercado
Notícias Principais

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 de mar. de 2026, 14:26 UTC

Conversa de Mercado
Notícias Principais

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 de mar. de 2026, 14:14 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de mar. de 2026, 14:14 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

Comparação entre Pares

Variação de preço

Celldex Therapeutics Inc Previsão

Preço-alvo

By TipRanks

69.8% parte superior

Previsão para 12 meses

Média 53.91 USD  69.8%

Máximo 90 USD

Mínimo 24 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Celldex Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

12 ratings

10

Comprar

1

Manter

1

Vender

Pontuação Técnica

By Trading Central

18.91 / 20.63Suporte e Resistência

Curto Prazo

Weak Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
help-icon Live chat